P = 0.031. Both groups had significant improvement of BODE index pre and post intervention, control group P = 0.001 (95% CI 0.865 to 1.959) and pedometer group P = 0.034 (95% CI 0.044 to 1.014).
Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan Background and Aims: Asthma-COPD overlap (ACO) is characterized by persistent airflow limitation with several features usually associated with asthma and COPD. Acute exacerbation (AE) of ACO and COPD is an important event that worsens prognosis. The aim of this study was to investigate and compare clinical characteristics and incidence of AE between patients with ACO and COPD.
Methods: We examined 45 ACO patients and 171 COPD patients who visited our hospital from 2014 to 2016. AE was defined as an episode requiring treatment with oral corticosteroid and/or antibiotics, or a visit to the emergency room, or hospitalization.
Results: The frequency of use of inhaled corticosteroids and a longacting beta2-agonist was significantly higher in the ACO patients vs the COPD patients (86.7 vs 30.4%, P < 0.001 and 88.9 vs 67.3%, P = 0.005, respectively). Patients with ACO had lower body mass index than those with COPD (21.2 vs 21.4 kg/m 2 , P = 0.031). There was a significant difference between the COPD and ACO patients in exposure to tobacco smoke (52.0 vs 35.4 pack-years, P = 0.011). There were no significant differences in age, gender ratio, and pulmonary function test results.
During the follow-up period (median, 517 days), 26 patients with ACO and 65 patients with COPD suffered AE. Log-rank test showed that ACO patients had a higher incidence rate of AE than COPD patients (P = 0.002). Methods: Illumina's 450 K DNA methylation microarray was used to identify differentially methylated loci (DML) in a discovery cohort of 12 ACO patients and 6 healthy subjects. DNA methylation levels were validated by pyro-sequencing in a validation cohort of 22 ACO patients, 48 pure COPD patients, and 10 healthy non-smokers.
Conclusion
Results: Seventy-five of the 228 COPD patients were identified as ACO, which was independently associated with total number of exacerbations both in the past and following one year. Microarray analysis identified 404 DMLs in ACO patients vs healthy non-smokers. In the validation cohort, both +30088 CpG site of the PDE9A gene and -296 CpG site of the ZNF323 gene were hypermethylated, while −47 CpG site of the SEPT8 gene was hypomethylated in the ACO vs pure COPD or nonsmokers. +348 CpG site of the CYSLTR1 gene, +125722 CpG site of the CCDC88C gene, and +1339 CpG site of the ADORA2B gene were all hypomethylated in COPD patients with severe airflow limitation, while -173 CpG site of the TIGIT gene were hypermethylated. -515 CpG site of the IFRD1 gene were hypomethylated in frequent exacerbators. DNA methylation levels over both -296 CpG site of the ZNF323 gene and +194 CpG site of the MPV17L gene were elevated after 1-year treatment in those with rapid lung function decline. Cigarette smoke extract and ovalbumin concurrent exposure result in over-expressions of the PDE9A, SEPT8, and IFRD1 genes. 
